Normal Tension Glaucoma, High Tension Glaucoma
Conditions
Interventions
Two groups:Gingko Biloba 240mg QD vs Placebo - Calcium tablets for 8 weeks
Sponsors
Professor Nathan Congdon, Department of Ophthalmology and Visual Science
Eligibility
Sex/Gender
Male
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: A. Definite glaucomatous VF (at least three contiguous points in one hemi-field abnormal below the 1% level, two of which are observed on three successive VF tests) and disc damage (CDR >= 0.7 and/or a rim width of = 22 mmHg on at least two occasions
Exclusion criteria
Exclusion criteria: Exclusion Criteria: a. Any history of dementia or other cognitive abnormality, or evidence on examination or history of non-ocular causes for VF loss. b. Any evidence of disc pallor, retinal abnormality or other finding on ocular examination to suggest an ocular cause other than glaucoma for the VF loss or disc abnormality. c. Need for surgical intervention of any kind, or change in medication within one month of initiating participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a. Visual field: MD, CPSD, and change in these two parameters before and after treatment over 8 weeks. b. Optic nerve blood flow, and change before and after treatment over 8 weeks. c. Visual function and change before and after treatment d. Effect of treatment type (GBE versus placebo) on the three above parameters e. Effect of glaucoma type (NTG versus pressure-dependent) on changes in VF, visual function and blood flow parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| f. Change in effect on blood flow, visual function and VF parameters with continued treatment over time with GBE (total of 8 months after cessation of randomized therapy); | — |
Countries
China
Contacts
Public ContactNathan Congdon
Outcome results
None listed